Compare CLWT & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | PASG |
|---|---|---|
| Founded | 1971 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | 24 |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 12.8M |
| IPO Year | 1996 | 2020 |
| Metric | CLWT | PASG |
|---|---|---|
| Price | $1.18 | $3.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.5M | 13.8K |
| Earning Date | 04-30-2026 | 11-17-2026 |
| Dividend Yield | ★ 11.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $3.29 |
| 52 Week High | $2.68 | $20.00 |
| Indicator | CLWT | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 54.57 |
| Support Level | $1.10 | $3.30 |
| Resistance Level | $1.36 | $5.03 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 11.79 | 98.36 |
Euro Tech Holdings Co Ltd is mainly a distributor of a wide range of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies, and power generation equipment, including recorders and power quality analyzers. The Company acts as an exclusive or non-exclusive distributor for manufacturers of such equipment to commercial customers and governmental agencies in Hong Kong and mainland China, as well as commercial customers in Macau. It has two operating segments: Trading and manufacturing, which generate maximum revenue and act as a distributor of water treatment equipment, laboratory instruments, analyzers, test kits, related supplies, and power generation equipment; and the Engineering segment. The Company generates maximum revenue from the PRC.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.